Navigation Links
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Date:4/20/2009

- Company will increase focus on HCV pipeline

- Conference call at 8:00 AM ET today

PRINCETON, N.J., April 20 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the company has decided to voluntarily terminate its Phase III QUASH studies of clevudine for the treatment of chronic hepatitis B (HBV) infection.

Pharmasset recently became aware of a number of spontaneous Serious Adverse Event reports and Events of Special Interest in patients receiving clevudine as prescribed therapy for hepatitis B in South Korea. Though only a small number of cases of mild to moderate myopathy, or muscle weakness associated with creatine kinase elevations, were reported in the QUASH studies, many of the patients in South Korea have had longer exposures to clevudine than patients in the QUASH studies and have reported more serious myopathy than have patients in the Pharmasset clinical trials. Given the number and severity of cases observed in South Korea, Pharmasset concluded it was in the best interest of patients to terminate the studies at this time.

"The safety of patients in the QUASH studies is our top priority and, therefore, we have decided to stop treatment with clevudine," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "Although the number of cases of myopathy in the QUASH trials was low and the severity was mild, more severe reports from other trials and post marketing surveillance led us to believe the risk benefit ratio for clevudine was insufficient to continue development. We would like to take this opportunity to thank patients and our investigators for their participation in the QUASH studies."

As part of the study shut down, Pharmasset plans
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
2. Pharmasset Reports Fiscal Year End 2008 Financial Results
3. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
4. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
5. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
6. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
9. Pharmasset Receives Notice of Allowance
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015 According to a new market ... Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, ... 2020", published by MarketsandMarkets, the global Neuromodulation Market is estimated ... $6.20 Billion by 2020, at a CAGR of 11.2% during ... 4 market data T ables and ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board of ... announced that Tamas Feitel has joined the ... Numotion after a highly successful 18 year career at ... driving strategy, profitability, and productivity to result in significant ... position was Chief Financial Officer for GE Healthcare Global ...
(Date:7/2/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Emerging Technologies, Competitive Landscape" report to ... in Clinical Chemistry and Immunodiagnostics: Global Challenges, ... seven-country strategic analysis of major business opportunities ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... Oct. 23 Novavax, Inc. (Nasdaq: NVAX ) a clinical-stage ... will be presenting at the 8th Annual BIO Investor Forum 2009 ... 2009 at the Palace Hotel in San Francisco, California. Mr. ... research and development progress. A link to the live presentation ...
... , HOLLISTON, Mass., Oct. 23 Nyer Medical Group, Inc., ... wholly-owned subsidiary of Nyer which does business under the name ... Walgreen Eastern Co., Inc. for the sale of a substantial ... of a total of 12 neighborhood pharmacies which includes the ...
Cached Medicine Technology:Novavax to Present at 8th Annual BIO Investor Forum 2009 2Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiary's Stock to Investors 2Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiary's Stock to Investors 3Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiary's Stock to Investors 4
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top ... mesothelioma with even minimal asbestos exposure. Click here to read the complete story ... of Hawaii Cancer Center, Cedars Sinai Medical Center, and New York University exposed mice ...
(Date:7/3/2015)... ... 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. ... Symposium . To be held from March 4th - 6th, the 2016 (a previous ... Galleria Dallas. , Designed to take participants from the basic training and fundamentals of ...
(Date:7/3/2015)... ... 2015 , ... B. E. Smith, the only full-service leadership ... national president recruitment for Regional Care, Inc. in Scottsbluff, Neb. One ... has recently placed more than 1,000 healthcare executives into organizations. , As ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national chief nursing officer recruitment ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... took place on June 25, 2015 at 1:00pm. The Association welcomed speaker C. ... pertaining to injured bicyclists and practical points of investigating these types of cases. ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2
... limited pressure to achieve the ,thin and beautiful, ideal have ... study looking at five factors that may help young women ... of a society where discontent with appearance is common among ... of Arizona in the US, and colleagues is published online ...
... stimulating immune cells to more effectively battle cancerous tumors, ... effect, driving these intracellular fighters to exhaustion, a Mayo ... Journal of Clinical Investigation . The ... testing the treatment,s ability to ramp up the body,s ...
... News) -- Children who wake up at night and are allowed ... to be overweight than kids put back into their own bed, ... children aged 2 to 6 who had an increased risk of ... were overweight before becoming pregnant or their mothers were poor. ...
... News) -- Everyone knows teen behavior is highly influenced by their ... influence whether or not a teen drinks alcohol or uses drugs. ... their child,s drug or alcohol use, or worse, condone it, that ... study found. "Among friendship groups with ,good parents, there,s a ...
... HealthDay Reporter , TUESDAY, May 8 (HealthDay News) -- Women who ... to worry about gaining weight after the device is implanted, new ... aged 15 to 44 who were using two different types of ... About half of the women had a non-hormonal IUD containing copper ...
... A Wayne State University researcher believes a better ... one day help at-risk adolescents transition more quickly to ... To further that understanding, Tim Bogg, Ph.D., assistant ... and Sciences, has received a three-year, $731,000 grant from ...
Cached Medicine News:Health News:Self-worth needs to go beyond appearance 2Health News:Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment 2Health News:Study: Kids Who Sleep in Parents' Bed Less Likely to Be Overweight 2Health News:Friends' Parents Can Sway Teens' Odds for Drinking, Smoking 2Health News:IUD Use Tied to Modest Weight Loss 2Health News:IUD Use Tied to Modest Weight Loss 3Health News:WSU researches patterns of heavy alcohol use and life commitments in at-risk young adults 2Health News:WSU researches patterns of heavy alcohol use and life commitments in at-risk young adults 3
... provide excellent protection and ease of use. ... closer to an adhesive in molecular weight ... to maintain viscosity at high shear rates, ... for superb performance during capsulorhexis, phaco, IOL ...
151 channels cover the entire head with a high density, with provisions for the eyes and ears. Patients and subjects are examined in a comfortable seated position or laying down....
... The Magnes 1300 C is ideal for ... brain and other parts of the body. Often ... its possibilites, including magnetocardiography, gastrointestinal tract, fetal, spinal ... ,The 1300 C, with its 67 detector ...
... neutral pH bone putty that contains calcium-based ... for decades in orthopedic surgery. These materials ... source of bone to help the patient ... microstructure to enhance bone regeneration, provide optimal ...
Medicine Products: